


**AMENDMENTS TO THE CLAIMS**

**This listing of claims will replace all prior versions and listings of claims in the application:**

**LISTING OF CLAIMS:**

1. (original): A triaza-cyclopenta[cd]indene derivative represented by the following formula [I]:



(wherein R<sup>1</sup> and R<sup>2</sup> are the same or different, and independently are hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkyl-C<sub>1-6</sub>alkyl, C<sub>1-6</sub>alkoxy-C<sub>1-6</sub>alkyl, hydroxy-C<sub>1-6</sub>alkyl, cyano-C<sub>1-6</sub>alkyl, carbamoyl-C<sub>1-6</sub>alkyl or di(C<sub>1-6</sub>alkyl)amino-C<sub>1-6</sub>alkyl, cyano, carbamoyl or aryl;

R<sup>3</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>3-7</sub>cycloalkyl-C<sub>1-6</sub>alkyl, halogen, C<sub>1-6</sub>alkoxy, C<sub>3-7</sub>cycloalkyloxy, C<sub>1-6</sub>alkylthio or -N(R<sup>6</sup>)R<sup>7</sup>;

R<sup>4</sup> is hydrogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl or C<sub>3-7</sub>cycloalkyl-C<sub>1-6</sub>alkyl;

R<sup>5</sup> is hydrogen, C<sub>1-6</sub>alkyl, aryl-C<sub>1-6</sub>alkyl or carbamoyl;

Ar is aryl or heteroaryl which aryl or heteroaryl is unsubstituted or substituted with 1 or more substituents, which are the same or different, selected from the group consisting of

halogen, C<sub>1-6</sub>alkyl, C<sub>3-7</sub>cycloalkyl, C<sub>2-6</sub>alkenyl, C<sub>2-6</sub>alkynyl, C<sub>1-6</sub>alkoxy, C<sub>1-6</sub>alkylthio, C<sub>1-6</sub>alkylsulfinyl, C<sub>1-6</sub>alkylsulfonyl, cyano, nitro, hydroxy, -CO<sub>2</sub>R<sup>8</sup>, -C(=O)R<sup>9</sup>, -CONR<sup>10</sup>R<sup>11</sup>, -OC(=O)R<sup>12</sup>, -NR<sup>13</sup>CO<sub>2</sub>R<sup>14</sup>, -S(=O)<sub>r</sub>NR<sup>15</sup>R<sup>16</sup>, trifluoromethyl, trifluoromethoxy, difluoromethoxy, fluoromethoxy and -N(R<sup>17</sup>)R<sup>18</sup>;

R<sup>8</sup> and R<sup>14</sup> are the same or different, and independently are hydrogen or C<sub>1-5</sub>alkyl, C<sub>3-8</sub>cycloalkyl, C<sub>3-8</sub>cycloalkyl-C<sub>1-5</sub>alkyl, aryl or aryl-C<sub>1-5</sub>alkyl;

R<sup>6</sup>, R<sup>7</sup>, R<sup>9</sup>, R<sup>10</sup>, R<sup>11</sup>, R<sup>12</sup>, R<sup>13</sup>, R<sup>15</sup>, R<sup>16</sup>, R<sup>17</sup> and R<sup>18</sup> are the same or different, and independently are hydrogen, C<sub>1-6</sub>alkyl or C<sub>3-7</sub>cycloalkyl;

r is 1 or 2) or individual isomers thereof or racemic or non-racemic mixtures of isomers thereof, or pharmaceutically acceptable salts and hydrates thereof.

2. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R<sup>3</sup> is C<sub>1-6</sub>alkyl; R<sup>4</sup> is hydrogen or C<sub>1-6</sub>alkyl; R<sup>5</sup> is hydrogen or C<sub>1-6</sub>alkyl; Ar is phenyl which phenyl is substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen, C<sub>1-3</sub>alkyl, C<sub>1-3</sub>alkoxy, C<sub>1-3</sub>alkylthio, trifluoromethyl, trifluoromethoxy and -N(R<sup>17</sup>)R<sup>18</sup> (wherein R<sup>17</sup> and R<sup>18</sup> are the same or different, and independently are hydrogen or C<sub>1-3</sub>alkyl); R<sup>1</sup>, R<sup>2</sup> and R<sup>4</sup> are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

3. (original): The triaza-cyclopenta[cd]indene derivative according to claim 1 represented by the formula [I], wherein R<sup>3</sup> is C<sub>1-3</sub>alkyl; R<sup>5</sup> is hydrogen or C<sub>1-3</sub>alkyl; Ar is phenyl which phenyl is

substituted with two or three substituents, which are the same or different, selected from the group consisting of halogen and C<sub>1-3</sub>alkyl; R<sup>1</sup>, R<sup>2</sup> and R<sup>4</sup> are as defined in claim 1, or pharmaceutically acceptable salts and hydrates thereof.

4. (currently amended): An antagonist for CRF receptors, comprising a triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1 ~~any one of claims 1 to 3~~, as an active ingredient.

5. (currently amended): Use of a triaza-cyclopenta[cd]indene derivative, a pharmaceutically acceptable salt thereof or its hydrate according to claim 1 ~~any one of claim 1 to 3~~, for the manufacture of a therapeutic agent as an antagonist for CRF receptors.